CN118678983A - Skin treatment device - Google Patents

Abstract

Provided is a skin treatment device comprising: a plurality of electrodes capable of contacting the skin of a user; a power source electrically connected to the plurality of electrodes; a control device for generating one or more output waveforms capable of being applied to skin via a plurality of electrodes based on a power source, the one or more output waveforms comprising one or more predetermined output waveforms having an alternating current waveform with a frequency between 10kHz and 200 kHz.

Description

Skin treatment device

Technical Field

The present invention relates to a skin treatment device.

Background

There is known a technique of applying a low-frequency output waveform and a high-frequency output waveform to skin.

Prior art literature

Patent literature

Patent document 1: international publication No. 2021/167109

Disclosure of Invention

Problems to be solved by the invention

However, in the above-mentioned conventional techniques, it is difficult to effectively improve the cosmetic effect or the like given to the skin of the user.

Accordingly, an object of the present disclosure is to effectively improve a cosmetic-related effect or the like imparted to the skin of a user.

Solution for solving the problem

In order to achieve the above object, in one aspect, the present invention provides a skin treatment device comprising: a plurality of electrodes capable of contacting the skin of a user; a power supply electrically connected to the plurality of electrodes; and a control device that generates one or more output waveforms capable of being applied to skin via a plurality of electrodes based on the power source, the one or more output waveforms including one or more predetermined output waveforms, the one or more predetermined output waveforms being an alternating current waveform having a frequency between 10kHz and 200 kHz.

Effects of the invention

According to the present invention, the cosmetic effect or the like applied to the skin of the user can be effectively improved.

Drawings

Fig. 1 is a perspective view showing the external appearance of a skin treatment device according to an embodiment of the present invention.

Fig. 2 is a 2-sided view showing the skin treatment device 1 of fig. 1.

Fig. 3 is an explanatory diagram of a control device incorporated in the skin treatment device 1 of the present embodiment.

Fig. 4 is a diagram showing an example of a hardware configuration of the control device.

Fig. 5A is an explanatory diagram of effects when a low-band high-frequency waveform and a high-band high-frequency waveform are combined, and is a diagram showing results of a cell test concerning collagen production.

Fig. 5B is an explanatory diagram of effects when the low-band high-frequency waveform and the high-band high-frequency waveform are combined, and is a diagram showing results of a cell test concerning hyaluronic acid production.

Fig. 6 is a graph showing the effect of combining a low-band high-frequency waveform and a dc pulse waveform according to the nicotinamide penetration effect verification result.

Fig. 7 is an explanatory diagram showing an example of a preferred combination form of various output waveforms.

Fig. 8 is an explanatory diagram showing another example of a preferred combination form of various output waveforms.

Detailed Description

Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings.

Fig. 1 is a perspective view showing the external appearance of the skin treatment device 1 of the present embodiment, fig. 2 is a 2-sided view of the skin treatment device 1 of fig. 1, and the left side is a side view and the right side is a front view.

The skin treatment device 1 of the present embodiment is in the form of a beauty device, and is configured to apply a beauty-related effect to the skin of the face of the user. However, in the modification, the skin treatment device 1 may be configured to apply similar beauty-related effects to an area other than the face of the user, in addition to or instead of the face of the user. The skin treatment device 1 may be used to exert an effect (for example, an effect of promoting percutaneous absorption of a drug) different from a cosmetic effect.

Cosmetic related effects may be arbitrary and may include relaxation elimination, tightening, fat burning, lifting, face thinning, increasing skin elasticity, luster and moisturization, or any combination of one or more thereof. Furthermore, the cosmetic related effects may be quantifiable effects or non-quantifiable effects.

The skin treatment device 1 of the present embodiment is configured to apply various outputs to the skin of the user by a plurality of electrodes in contact with the skin of the user, thereby applying (imparting) a cosmetic-related effect to the skin of the user.

The skin treatment device 1 of the present embodiment is portable and can be held by the hand of the user, but may be applied to a portable device that is supported movably by an arm or the like on a fixing device.

The skin treatment device 1 includes a grip portion 2 and a head portion 3. In this case, the user holds the grip portion 2 and places the head 3 at a desired portion (region) in his/her face, whereby various outputs from the skin treatment device 1 can be provided to the desired portion.

The grip portion 2 has a shape that is easily grasped by a user's hand. The grip 2 may include a user interface 20, and the user interface 20 includes various buttons such as a power on/off button, a mode switching button, an intensity adjusting button, and the like. The various buttons may be mechanical buttons or tactile switches. The grip portion 2 may be provided with a display portion (not shown) for displaying the state of the skin treatment device 1. The grip portion 2 may be provided with a third electrode 33 touched by a user's hand.

The head 3 is provided at the end of the grip 2. The head 3 may be fixed with respect to the grip 2, may be detachable, or may be movable with respect to the grip 2.

The head 3 is capable of contacting the skin of the user and has a shape suitable for contacting the skin of the user. For example, the head portion 3 may have a contact surface 3a in a substantially planar shape (including a curved shape having a large radius of curvature). In fig. 2, in a side view, the extending direction (basic surface) of the contact surface 3a is indicated by a chain line. In this case, the contact surface 3a is a plane which may be approximated to a substantially straight line in a side view. The shape of the contact surface 3a in the front view (shape when viewed in a direction perpendicular to the contact surface 3 a) is arbitrary, and may be, for example, rectangular, circular, elliptical, polygonal, or the like, and in the present embodiment, as an example, circular as shown in fig. 2.

The head 3 has a plurality of electrodes 30 provided on the contact surface 3 a. The plurality of electrodes 30 may protrude slightly from the basic surface of the contact surface 3a of the head 3 so as to easily contact the skin of the user.

In the present embodiment, the plurality of electrodes 30 includes a first electrode 31, a second electrode 32, and a third electrode 33 as an example. The first electrode 31 and the second electrode 32 are formed in a double-annular shape. Specifically, the first electrode 31 has an annular shape near the center of the contact surface 3a, and the second electrode 32 has an annular shape concentric with the first electrode 31 and has a larger diameter than the first electrode 31. The third electrode 33 is provided on the back side of the grip 2 (i.e., the side opposite to the user interface 20).

The electrode structure shown in fig. 1 and 2 is only an example, and the electrode structure is arbitrary as long as various output waveforms described below can be applied to the skin of the user. Therefore, for example, the present invention can be applied to various electrode structures such as concentric annular electrode structures of 3 or more, electrode structures arranged in a straight line, and electrode structures including annular electrodes separated in the circumferential direction.

Fig. 3 is an explanatory diagram of the control device 100 incorporated in the skin treatment device 1 of the present embodiment. Fig. 4 is a diagram showing an example of a hardware configuration of the control device 100. Fig. 2 schematically shows a peripheral device 160 associated with the hardware configuration of the control device 100.

The control device 100 is electrically connected to the power supply 90, and is electrically connected to the first electrode 31, the second electrode 32, and the third electrode 33. The power supply 90 may be implemented by an internal battery installed in the skin treatment device 1 and/or an external power supply connected to the skin treatment device 1. In addition, the control device 100 may have a power supply circuit or the like that generates various operation power supplies based on the power supply 90. In addition, the control device 100 may include a general-purpose processor, a special-purpose processor, an integrated circuit, an ASIC (application specific integrated circuit), or the like.

In the example shown in fig. 4, the control device 100 includes CPU (Central Processing Unit), RAM (Random Access Memory), 112, ROM (Read Only Memory), an auxiliary storage device 114, a drive device 115, a communication interface 117, and a wired transceiver 125 and a wireless transceiver 126 connected to the communication interface 117, which are connected through a bus 119.

The auxiliary storage 114 is, for example, HDD (Hard Disk Drive), SSD (Solid STATE DRIVE), or the like, and is a storage device that stores data related to application software or the like.

The wired transmitting/receiving unit 125 includes a transmitting/receiving unit capable of communicating using a wired network. Peripheral device 160 is connected to wired transceiver 125. However, some or all of peripheral devices 160 may be connected to bus 119 or wireless transceiver 126. In addition, the peripheral device 160 may include the above-described plurality of electrodes 30, a portable terminal such as a smart phone of a user, or the like. In the case of including a portable terminal, the user can perform various settings and the like relating to the skin treatment device 1 through the portable terminal.

The wireless transceiver 126 is a transceiver capable of communicating using a wireless network. The wireless network may include a cell phone wireless communication network, the internet, a virtual private network (VPN, virtual Private Network), a wide area network (WAN, wide Area Network), and the like. The Wireless transceiver 126 may include a near field Communication (NFC: NEAR FIELD Communication) unit, a Bluetooth (registered trademark) Communication unit, a Wi-Fi (Wireless-Fidelity) transceiver unit, an infrared transceiver unit, and the like.

The control device 100 may be connected to the recording medium 116. The recording medium 116 stores a predetermined program. The program stored in the recording medium 116 is installed in the auxiliary storage device 114 or the like of the control device 100 via the drive device 115. The installed predetermined program may be executed by the CPU111 of the control apparatus 100. For example, the recording medium 116 may be a recording medium such as a CD (Compact Disc) -ROM, a floppy disk, a magneto-optical disk, a semiconductor memory for electrically recording information such as a ROM, a flash memory, or the like. In addition, the recording medium 116 does not include a carrier wave.

The control device 100 generates one or more output waveforms based on the power supply 90 that can be applied to the skin via the plurality of electrodes 30.

In the present embodiment, the control device 100 generates an alternating-current waveform (hereinafter also referred to as "low-band high-frequency waveform M0") having a frequency between 10kHz and 200kHz (an example of a predetermined output waveform). In this case, the control device 100 generates one or more low-band high-frequency waveforms M0 that enable application to the skin of the user through the first electrode 31 and the second electrode 32. That is, the generated low-band high-frequency waveform M0 can be applied to the skin of the user using the first electrode 31 as the positive electrode (or negative electrode) and the second electrode 32 as the negative electrode (or positive electrode).

In this context, unless otherwise indicated, an "alternating current waveform" is not only a sine wave, but also a concept including any waveform having bipolar characteristics.

The low-band high-frequency waveform M0 in the present embodiment may be a rectangular wave, but preferably has a form of a sine wave, i.e., a form gradually varying toward a peak. In this case, inconvenience (e.g., discomfort to the user due to a sudden increase in current) that may occur in the case of a rectangular wave can be eliminated or reduced.

Here, the low-band high-frequency waveform M0 has a frequency of between 10kHz and 200kHz, and thus, when applied to the skin of a user, can be expected to have an effect of activating skin cells (cell activation) and maintaining elasticity (effect on dermis) itself.

Therefore, for example, when the skin treatment apparatus 1 is provided with one or more operation modes, the low-band high-frequency waveform M0 can be used in a predetermined operation mode corresponding to the skin lifting effect or a predetermined operation mode corresponding to an effect related to the skin lifting effect (such as an effect of activating cells of the skin and maintaining elasticity).

In addition, the low-band high-frequency waveform M0 can be expected to produce an advantageous effect (synergistic effect) than the effect of using other types of output waveforms alone by being combined with other types of output waveforms.

Fig. 5A is an explanatory diagram showing the effect of combining the low-band high-frequency waveform M0 and the high-frequency waveform M6, and is a diagram showing the results of a cell test concerning collagen production. Fig. 5B is a graph showing the effect of combining the low-band high-frequency waveform M0 and the high-frequency waveform M6, and shows the results of a cell test concerning hyaluronic acid production.

In fig. 5A and 5B, the "control section" is a result corresponding to the case where the head 3 of the skin treatment device 1 contacts the skin, but no output waveform is applied from the head 3 to the skin. The "high-band high frequency" corresponds to a result when an alternating-current waveform (hereinafter also referred to as "high-frequency waveform M6") having a frequency between 1MHz and 3MHz (one example of a sixth output waveform) is applied. In addition, "low band+high band high frequency" corresponds to a result when the low band high frequency waveform M0 and the high frequency waveform M6 are applied in combination. The combination of the low-band high-frequency waveform M0 and the high-frequency waveform M6 is a combination method in which the low-band high-frequency waveform M0 and the high-frequency waveform M6 are alternately applied.

Here, the test method is as follows.

(Step S1) NB1RGB cells were seeded at a density of 2.0X10 ⁵ cells/dis in a 60mm dish (CatNo. 353002, falcon, USA) and incubated in a CO2 incubator (CO 2 concentration=5%, 37 ℃) for 24 hours.

(Step S2) the test medium is replaced, and the beauty instrument is applied for 3 days every 24 hours according to the test conditions. In addition, the medium level and the temperature in the liquid before and after the application of the beauty device were measured. As an untreated cosmetic instrument sample treatment group, 1. Mu.M tretinoin (CASNo.302-79-4, wako, japan) was treated under the condition of only 3mL of a medium, and cultured for 72 hours.

(Step S3) the supernatant of the culture was recovered in a 15mL tube (Cat#23-2265, crystalgen, USA), and stored frozen (-20 ℃). The production-promoting effect of collagen and hyaluronic acid in the recovered culture supernatant was evaluated by Enzyme-Linked Immuno Sorbent Assay (ELISA). In addition, the number of cells of 60mm dish from which the culture supernatant was removed was evaluated by MTT assay.

The method for measuring collagen using ELISA method is as follows.

(Step S1) 150. Mu.L of PBS was placed in a high adsorption 96-well plate (Cat No.3855, thermo scientific, USA), and 50. Mu.L of the culture supernatant sample was added thereto, and the mixture was allowed to stand at 4℃overnight. Type I collagen solution (Cat No.009-001-103, RCK, USA) was used as a standard substance.

(Step S2) the microplate was washed with 200. Mu.L of PBS (-) (PBS-T, tween20: CASNo.9005-64-5, sigma-Aldrich, USA) containing 0.05% Tween20, 150. Mu.L of 1% BovineSerupalumbumin (BSA, catNo.PRL68700-50G, proliant, USA) solution was added, and left to stand at 37℃for 1 hour.

(Step S3) after washing with 200. Mu.L of PBS-T, 100. Mu.L of 100ng/mL Biotin-labeled anti-type I collagen antibody (Cat No.600-406-103, ROCKLAND, USA) solution was added, and the mixture was allowed to stand at 37℃for 1 hour.

(Step S4) after washing with 200. Mu.L of PBS-T, 100. Mu. L STREPTAVIDIN-HRP (Cat No. CJ30H-1, agilent Technologies, USA,1:10 000) solution was added and allowed to stand at room temperature for 30 minutes.

(Step S5) after washing with 200. Mu.L of PBS-T, 100μL 2,2'-azinobis(3-ethylbenzothiazoline-6-sulfonic acid)diammoniumsalt(ABTS,CatNo.5110-0010,KPL,USA) solution was added to confirm the color development.

(Step S6) after the dye in the 96-well plate was homogenized, absorbance at 405nm (OD 405) was measured with a microplate reader.

(Step S7) the collagen production rate of the beauty apparatus applicable group was calculated by setting the OD405 of the control to 100%. The value obtained by dividing OD405 of the beauty applicator-applicable group by OD570 measured by MTT assay was calculated as the collagen production rate per cell.

The method for measuring hyaluronic acid using the ELISA method is as follows:

(step S1) Hyaluronan Binding Protein (HABP, catNo.BC40, hokudo, japan,1:55 00) solution prepared with PBS was added to 100. Mu.L of the high adsorption 96-well plate and incubated overnight at 4 ℃.

(Step S2) the solid-phase HABP solution was removed, washed with 200. Mu.L of PBS-T solution, then 150. Mu.L of 1% BSA solution was added thereto, and incubated at room temperature for 1 hour.

(Step S3) the BSA solution was removed, and after washing with 200. Mu.L of PBS-T, 100. Mu.L of 100-fold diluted culture supernatant with PBS (-) was added and incubated at room temperature for 1 hour. Sodium hyaluronate (Cat No 087-04511, wako, japan) was used as the standard substance.

(Step S4) the culture supernatant was removed, washed with 200. Mu.L of PBS-T, and 100. Mu.L of a solution of biotin-labeled HABP (Cat No. BC41, hokudo, japan, 1:2000) prepared with PBS (-) containing 0.5% BSA was added thereto, and the mixture was allowed to stand at 4℃overnight.

(Step S5) the biotin-labeled HABP solution was removed, washed with 200. Mu.L of PBS-T, and 100. Mu.L of Strepitavidin-HRP solution (1:10000) prepared with 0.5% PBS (-) containing BSA was added thereto, followed by standing at room temperature for 30 minutes.

(Step S6) the Strepitavidin-HRP solution was removed, washed with 200. Mu.L of PBS-T, and then 100. Mu.L of ABTS solution was added thereto to confirm the color development.

(Step S7) after the dye in the 96-well plate was homogenized, absorbance at 405nm (OD 405) was measured with a microplate reader.

(Step S8) the OD405 of the control group was 100%, and the hyaluronic acid production rate of the suitable group for the beauty apparatus was calculated. The value obtained by dividing OD405 of the beauty applicator-applied group by OD570 measured by MTT assay was calculated as the hyaluronic acid production rate per cell.

As can be seen from fig. 5A and 5B, a better effect is obtained when a combination of the low-band high-frequency waveform M0 and the high-frequency waveform M6 is applied, than in the case where only the high-frequency waveform M6 is applied. Specifically, when the combination of the low-band high-frequency waveform M0 and the high-frequency waveform M6 is applied, as shown in fig. 5A, the effect related to collagen production increases by 5% compared with the case where only the high-frequency waveform M6 is applied, at the relative value to the control section. In addition, in the case where the combination of the low-band high-frequency waveform M0 and the high-frequency waveform M6 is applied, as shown in fig. 5B, the effect related to the generation of hyaluronic acid increases by 8% in the relative value to the control segment, as compared with the case where only the high-frequency waveform M6 is applied.

Thus, the low-band high-frequency waveform M0 is effective not only in combination with the high-frequency waveform M6 but also in combination with other output waveforms.

In the present embodiment, the other output waveforms include an output waveform in the form of a dc pulse (hereinafter also referred to as "dc pulse waveform M5") (an example of a fifth output waveform). Such a dc pulse waveform M5 can be expected to have effects of ion introduction into the dermis layer or the like, and by combining with the low-band high-frequency waveform M0, the same synergistic effects as in the case of combining with the low-band high-frequency waveform M0 and the high-frequency waveform M6 can be expected.

Herein, unless specifically mentioned, a "direct current pulse" is a concept including a pulse having a sharp peak or a pulse having any unipolar waveform (e.g., rectangular wave or triangular wave).

The control device 100 generates the dc pulse waveform M5 so as to be applicable to the skin of the user via the first electrode 31 or the second electrode 32 and the third electrode 33, or to be applicable to the skin of the user via the first electrode 31 and the second electrode 32 and the third electrode 33. At this time, the pair of electrodes may be a combination of the first electrode 31 and/or the second electrode 32 and the third electrode 33.

In this case, the control device 100 preferably generates a dc pulse waveform M5 having a frequency between 1kHz and 10 kHz. In addition, the frequency associated with the dc pulse waveform M5 may be calculated with a period of time from the rising edge (or falling edge) of one pulse to the rising edge (or falling edge) of the next pulse in the dc pulse train as one cycle. Further, when the period changes, the frequency related to the dc pulse waveform M5 may be calculated based on the average value.

Fig. 6 is a graph showing the effectiveness of the combination of the low-band high-frequency waveform M0 and the dc pulse waveform M5 based on the nicotinamide penetration effect verification result. In this case, the test was performed in the following order.

1) As a confirmation of skin stability (steady state), after washing the forearm, the amount of water evaporation was measured at the applied site for 15 minutes, and it was confirmed that there was no large fluctuation or damage.

2) As a quantitative measurement of skin treatment from the skin treatment device 1, a sample was dropped into the site of use. The sample was subjected to a circular motion for a predetermined period of time at a speed of 1 revolution per second. The control section (for control) was smeared over the entire test area using a spatula for 3 minutes. After the treatment, the remaining samples were rubbed with cotton, and the skin surface was rubbed with cotton impregnated with 50% ethanol solution for cleaning. The stratum corneum of the applicable site was peeled off with an adhesive tape, and the content of the peeled stratum corneum samples of the 2 nd to 5 th and 6 th to 10 th were quantified. In view of the electrical influence of the skin treatment apparatus 1, the process starts from the control section. In addition, the application sites and the application sequences are random to avoid any impact due to the test sites or the order of implementation.

In this case, as can be seen from fig. 6, the case of applying the combination of the low-band high-frequency waveform M0 and the dc pulse waveform M5 gives a better effect than the case of applying only the low-band high-frequency waveform M0 or applying only the dc pulse waveform M5. Specifically, when the combination of the low-band high-frequency waveform M0 and the dc pulse waveform M5 is applied, as shown in fig. 6, the effect on the penetration amount in the stratum corneum is a relative value with respect to the control segment, which is increased by 101% compared to when only the dc pulse waveform M5 is applied. In addition, when the combination of the low-band high-frequency waveform M0 and the dc pulse waveform M5 is applied, as shown in fig. 6, the effect related to the penetration amount in the stratum corneum is a relative value to the control section, which is increased by 51% compared to the case where only the low-band high-frequency waveform M0 is applied.

In addition, in the present embodiment, the other output waveforms include an alternating-current waveform (hereinafter also referred to as "low-frequency waveform M4") having a frequency between 5Hz and 1kHz (an example of a fourth output waveform). Such a low-frequency waveform M4 can be expected to exert an appropriate stimulation effect on the skin muscle layer, and the combination with the low-frequency waveform M0 can be expected to have the same synergistic effect as the combination of the low-frequency waveform M0 and the high-frequency waveform M6.

The control device 100 generates a low frequency waveform M4 so as to be capable of being applied to the skin of the user through the first electrode 31 and the second electrode 32. That is, the generated low-frequency waveform M4 can be applied to the skin of the user with the first electrode 31 as the positive electrode (or negative electrode) and the second electrode 32 as the negative electrode (or positive electrode).

In addition, as described above, each of the low-frequency waveform M4, the direct-current pulse waveform M5, and the high-frequency waveform M6 may be preferably combined into the low-frequency-band high-frequency waveform M0, but the combined low-frequency-band high-frequency waveforms M0 may be different from each other.

Specifically, the Low-frequency waveform M4 is preferably combined with a Low-frequency band high-frequency waveform M0 (hereinafter, also referred to as "Low-frequency band high-frequency waveform M3" for distinction) having a frequency between 10kHz and 100kHz (one example of the third output waveform). In this case, the Low-band high-frequency waveform M3 may be combined with the Low-frequency waveform M4 in such a manner that 10kHz is intermittently output. By combining such a Low-band high-frequency waveform M3 with a Low-frequency waveform M4, a further increase in the above-described synergistic effect can be expected.

In addition, the Low-band high-frequency waveform M3 and the Low-frequency waveform M4 are preferably combined in a continuously switched manner. In this case, the Low-band high-frequency waveform M3 and the Low-frequency waveform M4 may be continuous for a stop time of about 0.1 to 1.5 seconds, or may be continuous without a stop time. In addition, the Low-band high-frequency waveform M3 and the Low-frequency waveform M4 may be preferably combined in such a manner as to have a period (for example, a continuous period of 30 seconds or more) in which the ratio of the generation time of the Low-band high-frequency waveform M3 is 1/3 or more, preferably 1/2 or more.

Further, it is preferable to continuously generate the Low-band high-frequency waveform M3 and the Low-frequency waveform M4 in such a manner that the Low-band high-frequency waveform M3 follows the Low-frequency waveform M4. In this case, a further increase in the above synergistic effect can be expected as compared with the case where the Low-frequency waveform M4 is continuously generated in such a manner as to follow the Low-frequency band high-frequency waveform M3.

The skin treatment device 1 may have an operation mode (an example of a predetermined operation mode) in which the Low-frequency high-frequency waveform M3 and the Low-frequency waveform M4 are alternately and continuously generated, and as described later, the Low-frequency high-frequency waveform M3 and the Low-frequency waveform M4 may be continuously generated in combination with other output waveforms. In the operation mode in which the Low-band high-frequency waveform M3 and the Low-frequency waveform M4 are alternately and continuously generated, the period of time in which the Low-band high-frequency waveform M3 and the period of time in which the Low-frequency waveform M4 are generated are alternately generated. In this case, the length of each time period is arbitrary, but may be, for example, 1 second or more.

The dc pulse waveform M5 is preferably combined with a low-band high-frequency waveform M0 (hereinafter, also referred to as "Middle low-band high-frequency waveform M2" for distinction) having a frequency between 10kHz and 200kHz, more preferably between 40kHz and 150kHz (one example of the second output waveform). By combining such a Middle low-band high-frequency waveform M2 with the dc pulse waveform M5, a further increase in the above synergistic effect can be expected.

In this case, the frequency of the Middle low-band high-frequency waveform M2 may vary according to the component to be permeated. Specifically, the higher the frequency of the Middle low-band high-frequency waveform M2, the higher the permeation effect tends to be for the low-molecular, water-soluble, easily positively charged active ingredient. Therefore, when these relevant active ingredients become the object to be infiltrated, the frequency of the Middle low-band high-frequency waveform M2 is preferably between 50kHz and 180kHz, and more preferably around 130 kHz. In this case, the dc pulse waveform M5 is preferably positive dc stimulation.

In addition, the lower the output waveform frequency, the higher the permeation effect tends to be for an active ingredient having low molecular weight, water solubility, and easily negatively charged property. Therefore, when these relevant active ingredients become the object to be infiltrated, the frequency of the Middle low-band high-frequency waveform M2 is preferably between 50kHz and 160kHz, and more preferably around 70 kHz. Further, in this case, the direct current pulse waveform M5 is preferably negative direct current stimulation.

Further, for the low-molecular, water-soluble, hardly dissociable property in an aqueous solution or the active ingredient of the ampholyte, the frequency of the Middle low-band high-frequency waveform M2 is preferably between 40kHz and 190kHz, more preferably around 40 kHz.

In addition, the Middle low-band high-frequency waveform M2 and the dc pulse waveform M5 are preferably combined in a continuously switched manner. At this time, the Middle low-band high-frequency waveform M2 and the dc pulse waveform M5 may be continuous for a stop time of about 0.1 to 1.5 seconds, or may be continuous without a stop time. In addition, the Middle low-band high-frequency waveform M2 and the dc pulse waveform M5 may be combined in the following manner: the proportion of the generation time of the Middle low-band high-frequency waveform M2 is preferably 1/3 or more, and preferably 1/2 or more of a period of time (for example, a continuous period of time of 30 seconds or more).

In addition, it is preferable that the Middle low-band high-frequency waveform M2 and the direct-current pulse waveform M5 are continuously generated in such a manner that the direct-current pulse waveform M5 follows the Middle low-band high-frequency waveform M2. In this case, a further increase in the synergistic effect can be expected as compared with the case where the mid low-band high-frequency waveform M2 is continuously generated after the dc pulse waveform M5.

The skin treatment device 1 may have an operation mode (an example of a predetermined operation mode) in which the Middle low-frequency band high-frequency waveform M2 and the dc pulse waveform M5 are alternately and continuously generated, and as described later, the Middle low-frequency band high-frequency waveform M2 and the dc pulse waveform M5 may be continuously generated in combination with other output waveforms. In addition, in the operation mode in which the Middle low-band high-frequency waveform M2 and the direct-current pulse waveform M5 are alternately and continuously generated, the period in which the Middle low-band high-frequency waveform M2 and the period in which the direct-current pulse waveform M5 are alternately generated. In this case, the length of each time period is arbitrary, but may be, for example, 1 second or more.

The High-frequency waveform M6 is preferably combined with a low-frequency band High-frequency waveform M0 (hereinafter, also referred to as "High low-frequency band High-frequency waveform M1" for distinction) having a frequency between 150kHz and 200kHz, more preferably, a frequency around 165kHz (one example of the first output waveform). In addition, the frequency around 165kHz is a frequency in the range of ±10% with respect to the 165kHz error, and more preferably a frequency in the range of ±5% with respect to the 165kHz error. By combining such a High low-band High-frequency waveform M1 with a High-frequency waveform M6, further increase in the above synergistic effect can be expected.

In addition, the High low-band High-frequency waveform M1 and the High-frequency waveform M6 are preferably combined in a continuously switched manner. In this case, the High low-band High-frequency waveform M1 and the High-frequency waveform M6 may be continuous with a stop time of 0.1 to 1.5 seconds, or may be continuous without a stop time. Further, the High low-band High-frequency waveform M1 and the High-band High-frequency waveform M6 may be combined to have one cycle (for example, a continuous period of 30 seconds or more), wherein the ratio of the generation time of the High low-band High-frequency waveform M1 is preferably 1/3 or more, and preferably 1/2 or more.

In addition, it is preferable that the High low frequency band High frequency waveform M1 and the High frequency waveform M6 are continuously generated in such a manner that the High frequency waveform M6 follows the High low frequency band High frequency waveform M1 or that the High low frequency band High frequency waveform M1 follows the High frequency waveform M6. Or the High low-band High-frequency waveform M1 and the High-frequency waveform M6 may be continuously generated in such a manner that the High low-band High-frequency waveform M1 is interposed before and after the High-frequency waveform M6. That is, the High low-frequency band High-frequency waveform M1 and the High-frequency waveform M6 may preferably be continuously generated in such a manner that the High-frequency waveform M6 follows the High low-frequency band High-frequency waveform M1 and the High low-frequency band High-frequency waveform M1 follows the High-frequency waveform M6.

The skin treatment device 1 may have an operation mode (an example of a predetermined operation mode) in which the High low frequency band High frequency waveform M1 and the High frequency waveform M6 are alternately and continuously generated, and as described later, the High low frequency band High frequency waveform M1 and the High frequency waveform M6 may be continuously generated in combination with other output waveforms. In the operation mode in which the High low-band High-frequency waveform M1 and the High-frequency waveform M6 are alternately and continuously generated, the period of time in which the High low-band High-frequency waveform M1 is alternately generated and the period of time in which the High-frequency waveform M6 is generated. In this case, the length of each time period is arbitrary, but may be, for example, 1 second or more.

Next, preferred combinations of the above-described various output waveforms will be further described.

Fig. 7 is an explanatory diagram of an example of a preferred combination of the above-described various output waveforms. In fig. 7, time is represented by the horizontal axis, and the order of generation of various output waveforms is shown in time series.

The example high-frequency waveform M6, middle Low-frequency band high-frequency waveform M2, direct-current pulse waveform M5, low-frequency waveform M4, and Low-frequency band high-frequency waveform M3 shown in fig. 7 are repeatedly generated in this order as one unit. In this way, the skin treatment device 1 may have an operation mode (one example of a predetermined operation mode) in which various output waveforms shown in fig. 7 are output in a pattern shown in fig. 7.

In this case, the Middle low-band high-frequency waveform M2 between the high-frequency waveform M6 and the dc pulse waveform M5 will be combined with the high-frequency waveform M6 and with the dc pulse waveform M5, so that respective synergistic effects can be generated. In addition, the Low-band high-frequency waveform M3 following the Low-frequency waveform M4 can produce a synergistic effect with the relationship of the Low-frequency waveform M4. In addition, since the high-frequency waveform M6 is sandwiched between the Low-frequency band high-frequency waveform M3 and the Middle-Low frequency band high-frequency waveform M2, the effect of the high-frequency waveform M6 can be maximized.

Fig. 7 shows lengths Δt6, Δt2, Δt5, Δt4, and Δt3 of time periods in which the high-frequency waveform M6, middle Low-frequency band high-frequency waveform M2, direct-current pulse waveform M5, low-frequency waveform M4, and Low-frequency band high-frequency waveform M3 are generated. The lengths Δt6, Δt2, Δt5, Δt4, and Δt3 are arbitrary, but may be, for example, Δt6=15 seconds, Δt2=7 seconds, Δt5=5 seconds, Δt4=3 seconds, and Δt3=5 seconds, respectively. In addition, in this case, the various output waveforms may be preferably combined in a period having a ratio of 1/3 or more, preferably 1/2 or more (for example, a continuous period of 30 seconds or more) of the sum (=Δ2+Δ3) of the generation times of the Middle Low-band high-frequency waveform M2 and the Low-band high-frequency waveform M3.

Further, in the example shown in fig. 7, the low-frequency waveform M4 may be generated at a plurality of frequencies. For example, in a period of time of length Δt4, low frequency waveforms M4 of frequencies of 17Hz, 10Hz, and 33Hz may be sequentially generated for 1 second each.

In addition, in the example shown in fig. 7, the lengths Δt6, Δt2, Δt5, Δt4, and Δt3 may be the same for each repetition period, but may also be different. For example, in the initial period, the length of Δt6 may be set longer than other subsequent periods to improve the warming effect of the band high-frequency waveform M6.

Further, in the example shown in fig. 7, the combination of the high-frequency waveform M6, the Middle Low-frequency band high-frequency waveform M2, the direct-current pulse waveform M5, the Low-frequency waveform M4, and the Low-frequency band high-frequency waveform M3 may be kept constant during repetition for a predetermined number of times, or may be changed. For example, a part of the high-frequency waveform M6, the Middle Low-frequency waveform M2, the dc pulse waveform M5, the Low-frequency waveform M4, and the Low-frequency waveform M3 may be replaced with other output waveforms, or other output waveforms may be added together with the Low-frequency waveform M0.

Fig. 8 is an explanatory view of another example of a preferred combination scheme (form) of the above-described various output waveforms. In fig. 8, time is represented by the horizontal axis, and the order of generation of various output waveforms is shown in time series.

In the example shown in fig. 8, the repetition is performed in one unit of a period in which the High-frequency waveform M6 and the High-Low-band High-frequency waveform M1 are alternately generated (hereinafter also referred to as a "first period"), a period in which the dc pulse waveform M5 and the Middle-Low-band High-frequency waveform M2 are alternately generated (hereinafter also referred to as a "second period"), and a period in which the Low-frequency waveform M4 and the Low-band High-frequency waveform M3 are alternately generated (hereinafter also referred to as a "third period"). As such, the skin treatment device 1 may have an operation mode (one example of a predetermined operation mode) in which various output waveforms shown in fig. 8 are output in a pattern shown in fig. 8.

The length Δt61 of the first period, the length Δt52 of the second period, and the length Δt43 of the third period are arbitrary, respectively, but may be suitably generated by dividing each waveform in each period (period) at least 2 times or more. For example, the High-frequency waveform M6 and the High-low-frequency waveform M1 may be alternately generated 2 times or more in such a manner as to have an application time of 1 second or more, respectively. The same applies to the second period and the third period. The lengths Δt61, Δt52, and Δt43 may be the same or different from each other. In addition, in this case, these output waveforms may be combined with a period of time (for example, a continuous period of time of 30 seconds or longer) in which the ratio of the sum of the generation times of the High Low-band High-frequency waveform M1, the Middle Low-band High-frequency waveform M2, and the Low-band High-frequency waveform M3 is preferably 1/3 or more, and preferably 1/2 or more.

According to the example shown in fig. 8, the effects described above with reference to fig. 7 can also be obtained.

In the example shown in fig. 8, the lengths Δt61, Δt52, and Δt43 may be the same in each repetition period, but may also be different as in the example shown in fig. 7. For example, in the initial period, the length of Δt61 may be set longer than other subsequent periods to improve the warming effect of the high-frequency waveform M6.

In addition, in the example shown in fig. 8, the order of the first period, the second period, and the third period is not limited thereto, and may be arbitrary. For example, the second period, the first period, and the third period may be repeated in this order.

In addition, the example shown in fig. 8 and the example shown in fig. 7 may be implemented in combination. For example, the example shown in fig. 8 may be implemented in one cycle, and the example shown in fig. 7 may be implemented in another cycle after the one cycle.

The embodiments have been described in detail above, but the present invention is not limited to the specific embodiments, and various modifications and changes can be made within the scope described in the claims. All or a plurality of the constituent elements of the above embodiments may also be combined.

In addition, in the above-described embodiment, various processes are based on an electrical output waveform or the like, but are not limited thereto. For example, in addition to the electric output waveform, any one or more of a method using heat of a heater or the like, a method using light other than an LED (LIGHT EMITTING Diode) or light such as IPL (Intense Pulsed Light), a method using ultrasonic waves, a magnetic method, and a method using electromagnetic waves may be used.

In the above embodiment, the object to be permeated is arbitrary. The object is a substance that can be applied to the skin of a person, and various effects such as a cosmetic effect can be expected typically. The object may be, for example, various components contained in cosmetics and the like. Or the object may be various components contained in the skin external preparation. The purpose of use of the external skin preparation, pharmaceutical products, external medical products, and other substance carriers is arbitrary. In addition, the subject should include substances that have an effect on promoting percutaneous absorption of drugs that are metabolized in the liver in the drug-external product without fully functioning. The external preparation to be further transdermally absorbed is used for any purpose, including analgesic, antiinflammatory, whitening, moisturizer, anti-wrinkle, anti-inflammatory, antibacterial, and antiviral, regardless of the purpose of transdermal absorption of the external preparation. Several examples of useful ingredients suitable for permeation are listed.

At a pH value from weakly acidic to weakly basic

< Group of compounds positively (+) charged in aqueous solution >

Among the known ingredients having a whitening effect are tranexamic acid, tranexamic acid derivatives such as tranexamic acid butyl ester hydrochloride, and nicotinamide, but not limited to these, pyridoxine hydrochloride and its derivatives effective for acne and rough skin, benzalkonium chloride for sterilization and disinfection, and peptides having isoelectric points on the base side which are considered to be effective for improving wrinkles, for example, palmitoyl tripeptide-5, acetohexapeptide-8, dipeptide diaminobutyrylaniline and its derivatives. Examples of the allantoin, adefovir (aldioxa), carnitine hydrochloride, lysine, arginine, histidine, tryptophan, ornithine, and the like which are basic amino acids include ergothioneine, urea which is a humectant, and the like, but the present invention is not limited to these compounds, as long as they have a functional group that is +charged or polarized at a pH in the vicinity of weak acidity to weak alkalinity (the charged amount is small, and it is cationic).

< Compound group having negative (-) Charge in aqueous solution >

Examples of the sodium ascorbate include ascorbic acid, L-ascorbate 2-glucoside, sodium L-ascorbate phosphate, magnesium L-ascorbate phosphate, sodium L-ascorbate sulfate, sodium ascorbyl palmitate phosphate, and derivatives thereof, and sodium dl-alpha tocopherol phosphate, which are effective as whitening agents. Also comprises zinc p-phenolsulfonate, salicylic acid and sodium salt thereof, etc., and acidic amino acids such as sodium lactate, L-or DL-pyrrolidone carboxylic acid sodium solution, L-sodium glutamate, L-sodium aspartate, etc. Further, glycyrrhizic acid and salts thereof such as glycyrrhizic acid, dipotassium glycyrrhizinate and ammonium glycyrrhizinate, and substances having a functional group which is charged or polarized at a pH value in the vicinity of weak acidity to weak alkalinity such as guaifenesin sodium sulfonate and dilauryl glutamyl lysine Na (the charged amount is small, and the anionic nature is sufficient), but the present invention is not limited thereto.

< Compounds hardly dissociable in aqueous solution or ampholytes >

Kojic acid, arbutin, 4-n-butylresorcinol, 5 '-dipropyl-2, 2' -diol, erucic acid, 3-O-ethyl ascorbic acid, 3-glyceryl ascorbic acid, diglyceryl ascorbic acid, hexyl 3-glyceryl ascorbic acid, myristyl 3-glyceryl ascorbic acid, ascorbic acid derivatives such as 3-lauryl glyceryl ascorbic acid, D-panthenol, cholecalciferol, 3-O-isopropylmethylphenol, glycine, which are considered to have a whitening effect, may be mentioned: neutral amino acids such as proline, alanine, serine, acetylhydroxyproline, epsilon-aminocaproic acid, and gamma-aminobutyric acid, and derivatives thereof; amphoteric electrolytes such as trimethylglycine; sugars such as xylose, sorbitol, and mannitol; polyhydric alcohols such as butanediol, hexanediol, pentanediol, and glycerin; terpenes such as hydroxyquinol mercaptan, and the like. The insoluble substances such as fullerene, oryzanol, ceramide EOP, ceramide EOS, ceramide NG, caproyl olein, ceramide NP, N-stearoyl porphyrin sphingosine, N-stearoyl dihydrosphingosine, ceramide AG, ceramide AP, hydroxystearoyl porphyrin sphingosine, ceramide 6II, and phytosphingosine may be useful components, and may be contained in a liposome or not. Even plant and animal extracts, stem cell culture solutions, and culture supernatants are useful.

Examples of the flavonoid include, but are not limited to, soybean isoflavone, licorice root extract, licorice flavone, and licorice flavone. The extractum comprises: duck extract ET, radix Sophorae Flavescentis extract, swertia extract, radix Dauci Sativae and its root extract, semen glycines extract and semen glycines extract, folium Camelliae sinensis extract, galactose broth, mili No.11 (rice extract No. 11), astaxanthin liquid and Rhodophyta extract, placenta extract and placenta extract (1) - (5), water-soluble and hydrolyzed placenta extract, etc.

< Lipid and oil-soluble substance >

Including squalane, ascorbyl palmitate, ascorbyl dipalmitate, retinol acetate, retinyl palmitate, retinol and its derivatives such as hydrogenated retinol, retinol linoleate, tocopherol nicotinate, DL-alpha-tocopherol, d-delta-tocopherol, natural vitamin E, tocopherols and its derivatives such as DL-alpha-tocopherol acetate, stearyl glyceryl retinoate, phospholipids such as estradiol, astaxanthin, rice germ oil, sphingomyelin, synthetic, vegetable squalane, fatty acid esters of ascorbic acid such as guaiacol resin and guaiacol sulfonate, ascorbyl stearate, ascorbyl palmitate, bis (vegetable stearoyl/octyldodecyl) lauroyl glutamate, oil-soluble placenta (Plasenta), and the like.

< Compound having relatively high molecular weight and Polymer Compound >

Palmitoyl hexapeptide including human gene recombinant oligopeptide-1 and palmitoyl hexapeptide-4, palmitoyl pentapeptide, hydrolyzed collagen and its derivatives, hyaluronic acid Na, sodium hyaluronate and other hyaluronic acid and its derivatives, tremella polysaccharide, alkaline producing polysaccharide, and squaring.

Symbol description

1. Skin treatment device

2. Holding part

3. Head part

3A contact surface

10. Control device

14. Auxiliary storage device

15. Driving device

19. Bus line

20. User interface

30. Multiple electrodes

31. First electrode

32. Second electrode

33. Third electrode

100. Control device

116. Recording medium

117. Communication interface

125. Wired transceiver

126. And a wireless transmitting/receiving unit.

Claims (20)

1. A skin treatment device, comprising:

a plurality of electrodes capable of contacting the skin of a user;

A power supply electrically connected to the plurality of electrodes; and

A control device which generates one or more output waveforms capable of being applied to skin by the plurality of electrodes based on the power supply,

The one or more output waveforms include one or more predetermined output waveforms that are alternating current waveforms having a frequency between 10kHz and 200 kHz.

2. The skin treatment device according to claim 1, wherein,

The one or more predetermined output waveforms include at least any one of a first output waveform, a second output waveform, and a third output waveform,

The first output waveform has a frequency between 150kHz and 200kHz,

The second output waveform has a frequency between 40kHz and 150kHz,

The third output waveform has a frequency between 10kHz and 100 kHz.

3. The skin treatment device according to claim 1, wherein,

The one or more predetermined output waveforms include at least any two of a first output waveform, a second output waveform, and a third output waveform,

The first output waveform has a frequency between 150kHz and 200kHz,

The second output waveform has a frequency between 40kHz and 150kHz,

The third output waveform has a frequency between 10kHz and 100 kHz.

4. The skin treatment device according to claim 1, wherein,

The one or more predetermined output waveforms include a first output waveform, a second output waveform, and a third output waveform,

The first output waveform has a frequency between 150kHz and 200kHz,

The second output waveform has a frequency between 40kHz and 150kHz,

The third output waveform has a frequency between 10kHz and 100 kHz.

5. The skin treatment device according to claim 1, wherein,

The one or more predetermined output waveforms have a morphology that gradually varies toward a peak.

6. The skin treatment device according to claim 1, wherein,

The one or more output waveforms further include a fourth output waveform, the fourth output waveform being an alternating current waveform having a frequency between 5Hz and 1kHz,

The control means continuously generates the fourth output waveform and the predetermined output waveform.

7. The skin treatment device according to claim 2, wherein,

The one or more output waveforms further include a fourth output waveform, the fourth output waveform being an alternating current waveform having a frequency between 5Hz and 1kHz,

The control means continuously generates the fourth output waveform and the third output waveform.

8. The skin treatment device according to claim 7, wherein,

The control means continuously generates the fourth output waveform and the third output waveform in such a manner that the third output waveform follows the fourth output waveform.

9. The skin treatment device according to claim 1, wherein,

The one or more output waveforms further comprise a fifth output waveform in the form of a dc pulse,

The control means continuously generates the fifth output waveform and the predetermined output waveform.

10. The skin treatment device according to claim 2, wherein,

The one or more output waveforms further comprise a fifth output waveform in the form of a dc pulse,

The control means continuously generates the fifth output waveform and the second output waveform.

11. The skin treatment device according to claim 10, wherein,

The control means continuously generates the fifth output waveform and the second output waveform in such a manner that the fifth output waveform follows the second output waveform.

12. The skin treatment device according to claim 1, wherein,

The one or more output waveforms further include a sixth output waveform, the sixth output waveform being an alternating current waveform having a frequency between 1MHz and 3MHz,

The control means continuously generates the sixth output waveform and the predetermined output waveform.

13. The skin treatment device according to claim 2, wherein,

The one or more output waveforms further include a sixth output waveform, the sixth output waveform being an alternating current waveform having a frequency between 1MHz and 3MHz,

The control means continuously generates the sixth output waveform and the first output waveform.

14. The skin treatment device according to claim 13, wherein,

The control means continuously generates the sixth output waveform and the first output waveform in such a manner that the sixth output waveform follows the first output waveform or the first output waveform follows the sixth output waveform.

15. The skin treatment device according to claim 1, wherein,

The one or more output waveforms further comprise: a fourth output waveform having an alternating current waveform with a frequency between 5Hz and 1 kHz; a fifth output waveform in the form of a dc pulse; and a sixth output waveform having an alternating current waveform with a frequency between 1MHz and 3MHz,

The control means generates the fourth output waveform, the fifth output waveform, the sixth output waveform, and the predetermined output waveform in each of the fourth output waveform, the fifth output waveform, and the sixth output waveform in such a manner that the predetermined output waveform is continuous.

16. The skin treatment device according to claim 4, wherein,

The one or more output waveforms further comprise: a fourth output waveform having an alternating current waveform with a frequency between 5Hz and 1 kHz; a fifth output waveform in the form of a dc pulse; and a sixth output waveform having an alternating current waveform with a frequency between 1MHz and 3MHz,

The control device generates the fourth output waveform, the fifth output waveform, the sixth output waveform, and the predetermined output waveform in such a manner that the fourth output waveform is continuous with the third output waveform, the fifth output waveform is continuous with the second output waveform, and the sixth output waveform is continuous with the first output waveform.

17. The skin treatment device of claim 16, wherein the device comprises,

The control means generates the fourth output waveform, the fifth output waveform, the sixth output waveform, and the predetermined output waveform in such a manner that the third output waveform follows the fourth output waveform, the fifth output waveform follows the second output waveform, the sixth output waveform follows the first output waveform, or the first output waveform follows the sixth output waveform.

18. The skin treatment device according to claim 4, wherein,

The one or more output waveforms further comprise: a fourth output waveform having an alternating current waveform with a frequency between 5Hz and 1 kHz; a fifth output waveform in the form of a dc pulse; and a sixth output waveform having an alternating current waveform with a frequency between 1MHz and 3MHz,

The control means generates the fourth output waveform, the fifth output waveform, the sixth output waveform, and the predetermined output waveform in such a manner as to generate a first period of time in which the sixth output waveform is alternately continuous with the first output waveform, a second period of time in which the fifth output waveform is alternately continuous with the second output waveform, and a third period of time in which the fourth output waveform is alternately continuous with the third output waveform.

19. The skin treatment device according to claim 1, wherein,

One or more of the operation modes formed by the control device have a predetermined operation mode corresponding to a skin lifting effect or a predetermined operation mode corresponding to an effect related to a skin lifting effect,

The control means generates the one or more predetermined output waveforms in the predetermined mode of operation.

20. The skin treatment device of claim 19, wherein the device comprises,

The control device has a time period in which the ratio of the generation time of the one or more predetermined output waveforms is 1/3 or more and 30 seconds or more in the predetermined operation mode.